AREN1721: A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single AgentAxitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC)Across All Age Groups

This phase 2 study is examining the best treatments for TFE/Translocation type Renal Cell Carcinoma (tRCC). The best treatment for this type of kidney cancer is not known. This study is looking at 3 different treatment plans and trying to determine which treatment plan will be best.

Are you Eligible? (Inclusion Criteria)

• Patients must be at least 12 months of age
• Patients may be newly diagnosed or previously received treatment
• Patients must also meet all eligibility criteria as outlined in the study protocol